Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P02794 (ferritin)
 17,525 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In our study we have examined 314 samples of cyst fluid taken from women suffering from fibrocystic breast disease (gross cystic disease). We have subdivided the cyst fluid with respect to epithelial coating and we have related trophoblastic protein content of the cyst fluid with age, seriousness of illness, and cytology of epithelial lining. We have performed RIA analysis of the trophoblastic proteins betahCG, beta1-SP-1, and alphahCG and in a smaller (n=84) group of specimens we have also tested for CEA, TPA, and ferritin. Trophoblastic proteins were positive in cystic fluids but the biological meaning of this is not known and the values are not related to clinical manifestations, except in a group of patients with apocrine metaplasia in which we tried to find a relationship between fertile age and increased betahCG. This finding presumably has a prognostic meaning that can be further understood by epidemiologic studies (of dietary intake and evaluation of lipid metabolites) and by information about inflammatory state of cystic fluid.
 ...
PMID:Evaluation of tumor and trophoblastic marker concentration in breast cyst fluid. 235 3

Tumour markers are substances that occur at elevated blood levels in patients with certain tumours. When their specificity and sensitivity are known, markers can be used to monitor cancer patients. No single marker is specific and sensitive for a certain tumour, so a tumour-marker combination is used. The efficacy of CA 125, ferritin, TPA and CEA was demonstrated in 162 ovarian cancer patients. With the same combination, we found a statistically significant 91.7% correlation between the clinical course of the disease and the marker profile in 60 further patients. Tumour markers can also help make a prognosis. In 34 patients the marker profile accurately predicated the findings at second-look surgery. Thus, biochemical monitoring may supplant the second-look procedure. 68 patients were followed for a mean of 2.7 years after completion of chemotherapy. In 95.6% the tumour-marker analysis correlated with the clinical and radiologic course. This means that the end of chemotherapy depends on biochemical monitoring, and second-line therapy can be initiated sooner.
 ...
PMID:[Tumor marker combination versus second-look operation in ovarian cancer]. 237 87

In 50 patients with seminoma and in 50 with nonseminomatous germ cell tumors of the testis, serum levels of conventional markers (CEA, AFP, hCG) and ferritin were measured at the time of admission and during management. The conventional markers behaved as reported previously. After orchiectomy, elevated levels of ferritin were found in the presence as well as in the absence of tumor; the extent of these elevations was highly variable. Serial determinations of serum ferritin showed two patterns of variation. First, in patients treated with retroperitoneal lymph node dissection, irradiation, and chemotherapy regimens without platinum, decreasing levels of the conventional markers and serum ferritin were associated with response to therapy and increasing levels with relapse of tumor. Second, in patients treated with chemotherapy regimens containing cis-diamminedichloroplatinum, the conventional markers returned to normal values while the ferritin level doubled or tripled and returned to pretreatment or normal values only several weeks after therapy. Thus, it appears that hyperferritinemia was a sensitive index of platinum toxicity. We conclude that the serum ferritin level has no value in staging after orchiectomy but is a useful index of response to therapy during treatment with retroperitoneal lymph node dissection, irradiation or chemotherapy without platinum or relapse of tumor. During treatment with platinum, elevated levels might be explained as a possible toxic side effect of this drug.
 ...
PMID:Clinical usefulness of serum ferritin measurements in patients with testicular germ cell tumors. 240 96

Eleven potential biochemical markers were measured in serum from 33 patients with malignant and 13 with benign colorectal disease: four isoenzymes (creatine kinase-BB, homoarginine-sensitive alkaline phosphatase, salivary-type amylase, and macro-creatine kinase type 2), five specific proteins (ferritin, alpha 1-acid glycoprotein, C-reactive protein, alpha 1-antitrypsin, and ceruloplasmin), one oncofetal antigen (carcinoembryonic antigen, CEA), and one hormone (beta human choriogonadotropin). The sensitivity of individual markers for the detection of early-stage malignancy (n = 11) ranged from 0% to 64% (CEA 18%); for late-stage colon malignancy (n = 12) from 8% to 83% (CEA 83%). Specificity in patients (n = 10) with benign intestinal disease ranged from 80% to 100% (CEA 100%). The five most-sensitive markers--C-reactive protein, alpha 1-glycoprotein, CEA, macrocreatine kinase type 2, and homoarginine-sensitive alkaline phosphatase--were selected for use as a "colon panel." In retrospective comparison, use of the colon panel instead of CEA alone increased sensitivity by 17% and 64% for late-and early-stage cancer, respectively; specificity, however, decreased by 30%, but should improve with serial testing.
 ...
PMID:Multiple markers of malignancy in sera of patients with colorectal carcinoma: preliminary clinical studies. 241 37

Thirteen cases of pleomorphic adenoma were studied by both immunohistochemical and other histochemical methods. The exocrine cells and myoepithelial cells appear to produce similar cell products as their normal salivary gland counterparts. Keratin was found in both exocrine cells and myoepithelial cells. CEA, secretory component, and lactoferrin were detected only in the tumor exocrine cells with adenoid differentiation. S-100 protein, ferritin, fibronectin, laminin and elastin were detected only in the myoepithelial cells. The residual sugars glucosyl, mannosyl, galactosyl and fucosyl were identified in both cell types, in variably detectable amounts.
 ...
PMID:Product definition of pleomorphic adenoma of minor salivary glands. 241 23

We report a prospective study aimed at assessing the value of serum marker determinations in a supposedly healthy population to detect cancer and to identify individuals at high risk. We analyzed a group of 1,611 supposedly healthy subjects attending a cancer detection center, over a 1-5 year period and a control group of 100 cancer patients. Repeated determinations of the following markers were made: CEA, AFP, HCG, beta-HCG, beta 2-M, ferritin, beta 1-SP, all by radioimmunoassay. In the literature, marker determinations are considered not to be useful for cancer screening; in spite of this, we determined "normal" and "suspicious" levels for each marker and were able to define a group "at risk" that may harbor an early cancer (representing 23.6% of the total) and a "normal" group. The cancer detection rate was 45 0/00 (17/378) in the risk group and 3.2 0/00 in the "normal" one (4/1233). Our data show that markers could play a role in cancer screening.
 ...
PMID:Tumor markers for cancer detection. I. 243 Jul 4

Clinical usefulness of liver function tests, tumor markers including CA 19-9, CEA and serum ferritin and image diagnosis was discussed in regard to early diagnosis. Liver function tests were not useful, and tumor markers were highly positive, i.e., CA 19-9 was positive in 70.7% and CEA in 66.7%. However, these were low positive rate, in the early stage. Imaging techniques were very useful in detecting liver metastasis; US positive in 92.5%, CT 87.2% and angiography 93.1%. In the treatment of metastatic liver cancer, arterial chemotherapy and transarterial embolization are the major modality.
 ...
PMID:[Current status of diagnosis and treatment of metastatic liver cancer]. 243 44

The aims of this paper are to demonstrate the stainability of estrogen, CEA, and ferritin in breast carcinomas, fibroadenomas, and fibrocystic diseases; to examine whether the findings of endogenous estrogen using the immunohistochemical detection method are related to estrogen receptor (ER) assays; and to determine whether the stainability of estrogen, CEA, and ferritin were related to the prognosis of breast carcinomas. In breast cancer, the stainability of estrogen using the peroxidase-antiperoxidase (PAP) method was positively correlated with the dextran-coated charcoal (DCC) assay for ER. In breast cancers, the percentage of positive staining was 46% for estrogen, 48% for CEA, and 47% for ferritin. With all three stains, significant differences were observed between cancer and benign diseases. Cases that were both positive for estrogen staining and negative for CEA showed a good prognosis after the recurrence of disease. Our data suggest that the immunohistochemical staining of estrogen, CEA, and ferritin might predict the biological behavior of breast carcinomas and be a prognostically useful indicator of breast cancer patients.
 ...
PMID:Estrogen staining in breast carcinoma by PAP methods compared to CEA and ferritin staining. 243 74

Traditionally diagnosis of tumors is made by histopathology, because tumor markers are not sufficiently specific, and only low rates of positive cases have been observed. To induce free release of tumor markers into the blood, the IM injection of vitamin A and infrared-ray hyperthermia was used in 203 cancer patients. Blood samples were collected periodically to determine the levels of CEA, ferritin (FT), alpha-fetoprotein, sialic acid, and the ratio of ferritin to serum iron (FT/Fe). The analysis of each released tumor marker led to an increase in the rate of positive interpretations, indicating a linear correlation between tumor marker and tumor size. As a result of the evaluation of a combination assay of tumor markers using release induction, the rates of positive cases for any three of five markers were increased to 53, 65, and 94% in correlation with an increase in tumor size.
 ...
PMID:Correlation between tumor markers and tumor size. 243 76

Seven tumor markers (CA125, CA19-9, TPA, IAP, CEA, ferritin, LDH) were measured in 24 patients with ovarian cancer. The positive rates in untreated cases of ovarian cancer were 87.5% for CA125, 35.5% for CA19-9, 10% for CEA, 77.8% for IAP, 63.6% for TPA, 28.6% for LDH and 35.3% for ferritin. Among these, CA125 was the most available marker for detecting tumor growth or regression during each respective clinical course by serial measurement. Serial changes in serum alpha-fetoprotein (AFP) levels during treatment were studied among 27 patients with ovarian embryonal carcinoma. AFP decreased with a half-life of about 7 days, and was restored to the normal range within 10 weeks after the initial surgery and chemotherapy (VAC) in all cases. In subsequently fatal cases, AFP rose again during 10 to 30 weeks after the initial treatment.
 ...
PMID:[Significance of tumor markers in the treatment of patients with ovarian malignancies]. 244 93


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>